Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against norovirus infection. Findings show a 30% reduction in infection rates among vaccinated participants compared to those receiving a placebo, along with reduced viral...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.